Chun Yin Jerry Lau

Dr. Chun Yin Jerry Lau

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2018 in Bioconjugate Chemistry
Verified
Journal Article
Open access
BLBo Lou
Bo Lou
SKStefaan De Koker
Stefaan De Koker
CLChun Yin Jerry Lau
Chun Yin Jerry Lau
WHWim E. Hennink
Wim E. Hennink
Enrico MastrobattistaEnrico Mastrobattista
Enrico Mastrobattista
Vaccines based on messenger RNA (mRNA) have emerged as potent systems to elicit CD8+ T cell responses against various cancers and viral infectious diseases. The efficient intracellular delivery of mRNA molecules encoding antigens into the cytosol of antigen-presenting cells (APCs) is still challenging, requiring cell attachment, active uptake and subsequent endosomal escape. Here, we report a facile approach for the formulation of peptide-functionalized mRNA polyplexes using copper-free click chemistry to promote presentation of mRNA antigen by dendritic cells (DCs). After screening different membrane active peptides, GALA modified mRNA polyplexes (PPx-GALA) with a size around 350 nm and with a slightly negative surface charge (-7 mV), exhibited the highest EGFP-mRNA transfection in RAW 246.7 macrophages (~ 36%) and D1 dendritic cells (~ 50%) as compared to polyplexes decorated with melittin or LEDE peptides. Interestingly, we found that PPx-GALA enters DCs through sialic acid mediated endo/phagocytosis, which was not influenced by DC maturation. The PPx-GALA formulation exhibited 18-fold higher cellular uptake compared to a lipofectamine mRNA formulation without inducing cytotoxicity. Live cell imaging showed that PPx-GALA that were taken up by endocytosis induced calcein release from endosomes into the cytosol. DCs treated with PPx-GALA containing mRNA encoding for OVA displayed enhanced T cell responses and DC maturation. Collectively, these data provide a strong rationale for further study of this PPx-GALA formulation in vivo as a promising mRNA vaccine platform.

1 December 2019 in Journal of Controlled Release
Verified
Journal Article
Open access
NKNeda Kordalivand
Neda Kordalivand
ETElena Tondini
Elena Tondini
CLChun Yin Jerry Lau
Chun Yin Jerry Lau
TVTina Vermonden
Tina Vermonden
Enrico MastrobattistaEnrico Mastrobattista
Enrico Mastrobattista
CNCornelus F. van Nostrum
Cornelus F. van Nostrum
Recent studies have shown a high potency of protein-based vaccines for cell-mediated cancer immunotherapy. However, due to their poor cellular uptake, efficient immune responses with soluble protein antigens are often not observed. As a result of superior cellular uptake, nanogels loaded with antigenic peptides were investigated in this study as carrier systems for cancer immunotherapy. Different synthetic long peptides (SLPs) containing the CTL and CD4+ T-helper (Help) epitopes were synthesized and covalently conjugated via disulfide bonds to the polymeric network of cationic dextran nanogels. Cationic nanogels with a size of 210 nm, positive zeta potential (+24 mV) and high peptide loading content (15%) showed triggered release of the loaded peptides under reducing conditions. An in vitro study demonstrated the capability of cationic nanogels to maturate dendritic cells (DCs). Importantly, covalently SLP-loaded nanogels adjuvanted with poly(I:C) showed superior CD8+ T cell responses compared to soluble peptides and nanogel formulations with physically loaded peptides both in vitro and in vivo. In conclusion, covalently SLPs-loaded cationic nanogels are a promising system to provoke immune responses for therapeutic cancer vaccination.

1 September 2013 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
ECEdward P. Carter
Edward P. Carter
CLChun Yin Jerry Lau
Chun Yin Jerry Lau
DTDavid Tosh
David Tosh
SWStephen Geoffrey Ward
Stephen Geoffrey Ward
RMRandall J. Mrsny
Randall J. Mrsny

25 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MTMaarten K. Nijen Twilhaar
Maarten K. Nijen Twilhaar
LCLucas Czentner
Lucas Czentner
JGJoanna Grabowska
Joanna Grabowska
AAAlsya Affandi
Alsya Affandi
CLChun Yin Jerry Lau
Chun Yin Jerry Lau
JHJoke M. M. Den Haan
Joke M. M. Den Haan
Despite promising progress in cancer vaccination, therapeutic effectiveness is often insufficient. Cancer vaccine effectiveness could be enhanced by targeting vaccine antigens to antigen-presenting cells, thereby increasing T-cell activation. CD169-expressing splenic macrophages efficiently capture particulate antigens from the blood and transfer these antigens to dendritic cells for the activation of CD8+ T cells. In this study, we incorporated a physiological ligand for CD169, the ganglioside GM3, into liposomes to enhance liposome uptake by CD169+ macrophages. We assessed how variation in the amount of GM3, surface-attached PEG and liposomal size affected the binding to, and uptake by, CD169+ macrophages in vitro and in vivo. As a proof of concept, we prepared GM3-targeted liposomes containing a long synthetic ovalbumin peptide and tested the capacity of these liposomes to induce CD8+ and CD4+ T-cell responses compared to control liposomes or soluble peptide. The data indicate that the delivery of liposomes to splenic CD169+ macrophages can be optimized by the selection of liposomal constituents and liposomal size. Moreover, optimized GM3-mediated liposomal targeting to CD169+ macrophages induces potent immune responses and therefore presents as an interesting delivery strategy for cancer vaccination.

17 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DBDaniëlle ter Braake
Daniëlle ter Braake
NBNaomi Benne
Naomi Benne
CLChun Yin Jerry Lau
Chun Yin Jerry Lau
Enrico MastrobattistaEnrico Mastrobattista
Enrico Mastrobattista
FBF. (Femke) Broere
F. (Femke) Broere
The current treatment of autoimmune and chronic inflammatory diseases entails systemic immune suppression, which is associated with increased susceptibility to infections. To restore immune tolerance and reduce systemic side effects, a targeted approach using tolerogenic dendritic cells (tolDCs) is being explored. tolDCs are characterized by the expression of CD11c, the major histocompatibility complex (MHC)II and low levels of co-stimulatory molecules CD40 and CD86. In this study, tolDCs were generated using a human-proteoglycan-derived peptide (hPG) and all-trans retinoic acid (RA). RA-tolDCs not only display a tolerogenic phenotype but also can induce an antigen-specific regulatory T cell (Treg) response in vitro. However, further analysis showed that RA-tolDCs make up a heterogeneous population of DCs, with only a small proportion being antigen-associated tolDCs. To increase the homogeneity of this population, 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG)-containing liposomes were used to encapsulate the relevant antigen together with RA. These liposomes greatly enhanced the proportion of antigen-associated tolDCs in culture. In addition, in mice, we showed that the liposomal co-delivery of antigen and RA can be a more targeted approach to induce antigen-specific tolerance compared to the injection of RA-tolDCs, and that these liposomes can stimulate the generation of antigen-specific Tregs. This work highlights the importance of the co-delivery of an antigen and immunomodulator to minimize off-target effects and systemic side effects and provides new insights in the use of RA for antigen-specific immunotherapy for autoimmune and chronic inflammatory diseases.

11 February 2024 in Advanced Healthcare Materials
Verified
Journal Article
Open access
NBNaomi Benne
Naomi Benne
DBDaniëlle ter Braake
Daniëlle ter Braake
DPDeja Porenta
Deja Porenta
CLChun Yin Jerry Lau
Chun Yin Jerry Lau
Enrico MastrobattistaEnrico Mastrobattista
Enrico Mastrobattista
FBF. (Femke) Broere
F. (Femke) Broere
There is no curative treatment for chronic auto‐inflammatory diseases including rheumatoid arthritis, and current treatments can induce off‐target side effects due to systemic immune suppression. This work has previously shown that dexamethasone‐pulsed tolerogenic dendritic cells loaded with the arthritis‐specific antigen human proteoglycan can suppress arthritis development in a proteoglycan‐induced arthritis mouse model. To circumvent ex vivo dendritic cell culture, and enhance antigen‐specific effects, drug delivery vehicles, such as liposomes, provide an interesting approach. Here, this work uses anionic 1,2‐distearoyl‐sn‐glycero‐3‐phosphoglycerol liposomes with enhanced loading of human proteoglycan‐dexamethasone conjugates by cationic lysine tetramer addition. Antigen‐pulsed tolerogenic dendritic cells induced by liposomal dexamethasone in vitro enhanced antigen‐specific regulatory T cells to a similar extent as dexamethasone‐induced tolerogenic dendritic cells. In an inflammatory adoptive transfer model, mice injected with antigen‐dexamethasone liposomes have significantly higher antigen‐specific type 1 regulatory T cells than mice injected with antigen only. The liposomes significantly inhibit the progression of arthritis compared to controls in preventative and therapeutic proteoglycan‐induced arthritis mouse models. This coincides with systemic tolerance induction and an increase in IL10 expression in the paws of mice. In conclusion, a single administration of autoantigen and dexamethasone‐loaded liposomes seems to be a promising antigen‐specific treatment strategy for arthritis in mice.